Allorion has established and validated a mass spectrometry-based allosteric inhibitor screening platform and a synthetic lethality target/molecule discovery platform based on phenotypic, chemical, and CRISPR screening.

The company owns a proprietary library of nearly 200,000 high-quality small molecule compounds, enabling thorough and efficient screening.

In January 2024, Allorion entered into an exclusive option and global license agreement with AstraZeneca to develop and commercialize a novel epidermal growth factor receptor (EGFR) L858R mutated allosteric inhibitor. In return, Allorion became eligible for upfront and near-term payments of up to $40 million, and additional development and commercial milestone payments of over $500 million, as well as tiered royalties on net sales worldwide.